Wells Fargo & Company Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $207.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lifted by Wells Fargo & Company from $161.00 to $207.00 in a research note released on Tuesday, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on ALNY. Chardan Capital reissued a buy rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. StockNews.com raised Alnylam Pharmaceuticals from a hold rating to a buy rating in a report on Monday, April 29th. Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a buy rating in a research note on Monday, June 24th. Canaccord Genuity Group reiterated a buy rating and set a $283.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, June 21st. Finally, William Blair reissued an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Eight research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $247.09.

Alnylam Pharmaceuticals Stock Down 1.6 %

ALNY stock opened at $243.00 on Tuesday. The stock has a 50-day simple moving average of $159.86 and a two-hundred day simple moving average of $164.73. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $252.87. The firm has a market capitalization of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the prior year, the firm posted ($1.40) EPS. Alnylam Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -3.75 EPS for the current fiscal year.

Insider Activity

In related news, CFO Jeffrey V. Poulton sold 1,605 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the sale, the chief financial officer now owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the completion of the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at approximately $6,674,052. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,357 shares of company stock valued at $13,436,711. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Harbor Capital Advisors Inc. raised its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares in the last quarter. EP Wealth Advisors LLC lifted its position in Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 71 shares during the period. Commerce Bank boosted its stake in Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after acquiring an additional 77 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares during the period. Finally, Metis Global Partners LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock valued at $839,000 after purchasing an additional 94 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.